Ref (type)	Population	Outcome, Interventions	Results and statistical analysis	Effect size	Favours
Adverse effects
Systematic review	482 people 4 RCTs in this analysis	Any adverse effect with risperidone (dose range 2–10 mg/day) with placebo Absolute results not reported	RR 1.04 95% CI 0.94 to 1.15		Not significant
Systematic review	198 people Data from 1 RCT	QTc prolongation (corrected QT interval >450 ms or >10% increase from baseline) with risperidone (6 mg/day) with placebo Absolute results not reported	RR 7.58 95% CI 0.40 to 144.9		Not significant
Systematic review	655 people 5 RCTs in this analysis	Agitation with risperidone (dose range 2–16 mg/day) with placebo Absolute results not reported	RR 0.96 95% CI 0.73 to 1.26		Not significant
Systematic review	290 people 2 RCTs in this analysis	Sedation with risperidone with placebo Absolute results not reported	RR 1.31 95% CI 0.83 to 2.04		Not significant
Systematic review	911 people 6 RCTs in this analysis	Somnolence with risperidone with placebo Absolute results not reported	RR 1.39 95% CI 0.97 to 1.98		Not significant
Systematic review	323 people 2 RCTs in this analysis	Serum prolactin increase >23 ng/mL with risperidone (6 mg/day) with placebo Absolute results not reported	RR 12.54 95% CI 5.11 to 30.79	Large effect size	placebo
Systematic review	202 people Data from 1 RCT	Dry mouth with risperidone (6 mg/day) with placebo Absolute results not reported	RR 2.43 95% CI 0.65 to 9.12		Not significant
Systematic review	376 people 3 RCTs in this analysis	Any significant extrapyramidal symptom with risperidone (dose range 2–16 mg/day) with placebo Absolute results not reported	RR 1.40 95% CI 0.93 to 2.10		Not significant
Systematic review	42 people Data from 1 RCT	No improvement on Abnormal Involuntary Movement Scale (AIMS) score with risperidone (6 mg/day) with placebo Absolute results not reported	RR 0.30 95% CI 0.15 to 0.61	Moderate effect size	placebo
Systematic review	223 people Data from 1 RCT	No improvement on Barnes Akathisia Scale score with risperidone (mean dose 4.7 mg/day [SD 0.9 mg/day]) with placebo Absolute results not reported	RR 0.06 95% CI 0.03 to 0.12	Large effect size	placebo
Systematic review	44 people Data from 1 RCT	Needing medication for extrapyramidal symptoms with risperidone (dose range 2–16 mg/day) with placebo Absolute results not reported	RR 1.17 95% CI 0.47 to 2.92		Not significant
Systematic review	428 people 2 RCTs in this analysis	Akathisia with risperidone with placebo Absolute results not reported	RR 2.20 95% CI 0.88 to 5.49		Not significant
Systematic review	202 people Data from 1 RCT	Dystonia with risperidone (6 mg/day) with placebo Absolute results not reported	RR 11.44 95% CI 0.64 to 204.21		Not significant
Systematic review	323 people 2 RCTs in this analysis	Hypertonia with risperidone (6 mg/day) with placebo Absolute results not reported	RR 2.01 95% CI 0.87 to 4.64		Not significant
Systematic review	428 people 2 RCTs in this analysis	Tremor with risperidone with placebo Absolute results not reported	RR 1.34 95% CI 0.14 to 12.69		Not significant
Systematic review	42 people Data from 1 RCT	Mean difference in average endpoint score for AIMS with risperidone (6 mg/day) with placebo Absolute results not reported	Mean difference –5.4 95% CI –8.48 to –2.32	Effect size not calculated	placebo
Systematic review	223 people Data from 1 RCT	Mean difference in change from baseline in AIMS with risperidone (4.7 mg/day [SD 0.9 mg/day]) with placebo Absolute results not reported	Mean difference 0.4 95% CI 0.32 to 0.48	Effect size not calculated	placebo
Systematic review	223 people Data from 1 RCT	Mean difference in change from baseline in Simpson-Angus Scale with risperidone (4.7 mg/day [SD 0.9 mg/day]) with placebo Absolute results not reported	Mean difference 0.5 95% CI 0.42 to 0.58	Effect size not calculated	placebo
Systematic review	61 people Data from 1 RCT	Mean difference in white blood cell count with risperidone (3 mg/day) with placebo Absolute results not reported	Mean difference +0.66 95% CI –0.20 to +1.52		Not significant
Systematic review	56 people Data from 1 RCT	Mean difference in cholesterol (mg/dL) with risperidone (3 mg/day) with placebo Absolute results not reported	Mean difference –6.60 mg/dL 95% CI –29.05 mg/dL to +15.85 mg/dL		Not significant
Systematic review	64 people Data from 1 RCT	Weight gain with risperidone (3 mg/day) with placebo Absolute results not reported	RR 1.00 95% CI 0.40 to 2.52		Not significant
Systematic review	303 people 2 RCTs in this analysis	>7% increase in weight from baseline with risperidone (6 mg/day) with placebo Absolute results not reported	RR 5.14 95% CI 1.79 to 14.73	Large effect size	placebo
Systematic review	64 people Data from 1 RCT	Mean weight gain (kg) with risperidone (3 mg/day) with placebo Absolute results not reported	Mean difference +3.10 kg 95% CI –6.57 kg to +12.77 kg		Not significant
Systematic review	160 people Data from 1 RCT	Somnolence 24% with risperidone (1–3 mg/day) 12% with risperidone (4–6 mg/day) 4% with placebo Absolute numbers not reported	Significance assessment not performed
Systematic review	160 people Data from 1 RCT	Extrapyramidal symptoms 9% with risperidone (1–3 mg/day) 16% with risperidone (4–6 mg/day) 4% with placebo Absolute numbers not reported	Significance assessment not performed